Uday R. Popat, MD, on Post-Transplant Cyclophosphamide Following Myeloablative Busulfan as GVHD Prophylaxis

Video

Uday R. Popat, MD, spoke about how use of post-transplant cyclophosphamide vs tacrolimus plus methotrexate to prevent graft-vs-host disease following matched donor hematopoietic cell transplantation for acute myeloid leukemia could impact the standard of care.

CancerNetwork® spoke with Uday R. Popat, MD, professor and deputy chair ad interim in the Department of Stem Cell Transplantation, Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center in Houston, during the 2022 Tandem Meeting about the impact of results regarding post-transplant cyclophosphamide following myeloablative busulfan and matched donor hematopoietic cell transplantation to prevent graft-vs-host disease (GVHD) for patients with acute myeloid leukemia and myelodysplastic syndrome. Results of the trial (NCT02250937) showed that the regimen helped to reduce severe GVHD and nonrelapse mortality vs standard methotrexate/tacrolimus. Additionally, he spoke about implementation of the regimen and its potential as standard therapy going forward.

Transcript:

There are other studies which are randomizing the use of post-transplant cyclophosphamide vs tacrolimus plus methotrexate, and they will add to the literature. We believe that in many centers, post-transplant cyclophosphamide may become the standard for GVHD prophylaxis. In our center, we are seeing these results first. For us, this fractionated (see note on the side) busulfan regimen along with post-transplant cyclophosphamide is the go-to regimen.

This idea of giving a longer regimen or giving a regimen over a 3-week period allows a reduction in mortality and delivery of this particular treatment to all the patients. The idea itself is a simple idea. All you’re doing is spreading out your regimen, but the impact is tremendous. To me, it’s a very disruptive idea.

Reference

Popat UR, Mehta Rs, Bassett R, et al. Post-transplant cyclophosphamide versus tacrolimus and methotrexate to prevent graft-versus-host-disease in recipients of matched donor transplantation: comparison of sequential cohorts in a prospective trial. Presented at the 2022 Tandem Meeting; Salt Lake City, Utah; April 23-26, 2022. Poster 379.

Recent Videos
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Related Content